Patients with psoriasis treated with higher doses of oral zasocitinib showed significant improvement compared to those treated with a placebo in a phase 2b study. The study included patients with moderate to severe plaque psoriasis who received daily doses of 15 mg and 30 mg of zasocitinib. Results showed greater changes in mean PASI scores in the treatment groups compared to the placebo group, with improvements evident as early as week 2 and continuing through week 12. Phase 3 trials are ongoing to further evaluate the efficacy of zasocitinib across multiple endpoints in a larger population.
Source link
Zasocitinib meets proof of concept in plaque psoriasis
